Register now for our vital and insightful health updates, and get four free health reports to help you live more healthily.
A new US study shows that women taking tamoxifen to control cancer in one breast have a greatly increased risk of developing a tumour in the other breast.
Between 1990 and 1998, researchers followed nearly 9000 women who were diagnosed with a primary localised or regional invasive breast cancer in one breast only.
The women were aged 50 years or older, and were receiving hormonal therapy (tamoxifen) but not chemotherapy. They were followed until either the study ended, a cancer developed in the other breast, or they died
The researchers found that, while tamoxifen apparently protects against oestrogen-receptor (ER)-positive tumours, tamoxifen users had a nearly fivefold increased risk of developing an ER-negative tumour in the healthy breast. ER-negative tumours are not only more difficult to treat, but are also associated with a high death rate and an 8-35 per cent lower five-year survival rate (J Natl Cancer Inst, 2001; 93: 1008-13).
Tumours - Modern medicine has only its singleminded one-size-fits-all treatment for all types of tumours - with very little evidence of success. However, altern...
Death rate plunge: not from screening - Health officials who have been congratulating their extensive mammogram screening programmes as the reason for the sudden drop in breast cancer deaths...
Air pollution control reduces death rate - Irish researchers have found that measures to control air pollution have dramatically reduced the death rate from respiratory and cardiovascular disea...
Caesarean: It triples the death rate in newborns - Babies born by Caesarean section are three times more likely to die soon afterwards than those born naturally, a new study has discovered.
Tamoxifen: - The cancer drug that causes hepatitis (and cancer, too) - The drug company giveth, and it taketh away, too. The thought came to mind after we looked at the success of the drug tamoxifen in fighting - and pre...
Chemotherapy - When it works, when it doesn't - To attempt to separate fact from the vast fiction propagated about both orthodox and alternative treatment of cancer, we have produced a special cance...
Tamoxifen - The breast cancer drug tamoxifen-marketed in the UK as Emblon, Noltam and Tamofen, and as Nolvadex in the US and the UK-has been enjoying some favoura...
Surgery: Cancer op fails to clear tumour cells in 70 per cent of patients - Tumour cells are left in the body of two-thirds of patients who undergo so-called curative cancer surgery. The survival rate isn’t too impressive eit...
Register for our health updates and free gifts.